Literature DB >> 28927296

In vivo MR spectroscopy predicts high tumor grade in endometrial cancer.

Sigmund Ytre-Hauge1,2, Morteza Esmaeili3, Torill E Sjøbakk3, Renate Grüner1,4, Kathrine Woie5,6, Henrica M Werner5,6, Camilla Krakstad5,6, Line Bjørge5,6, Øyvind O Salvesen7, Ingunn M Stefansson8, Jone Trovik5,6, Tone F Bathen3, Ingfrid S Haldorsen1,2.   

Abstract

Background In vivo magnetic resonance spectroscopy (MRS) enables non-invasive measurements of tumor metabolites. Choline-containing metabolites play a key role in tumor metabolism. Purpose To explore whether preoperative MRS-derived tumor choline levels are associated with clinical and histological features in endometrial carcinomas. Material and Methods Preoperative pelvic magnetic resonance imaging (MRI) (1.5T), including structural and diffusion-weighted imaging and localized multivoxel proton MR (1H-MR) spectroscopy, was performed in 77 prospectively included patients with histologically confirmed endometrial carcinomas. Relative levels of total choline-containing metabolites (tCho) in tumor and myometrium were measured using the ratios: tCho/Creatine; tCho/Water; and tCho/Noise. MRS parameters were analyzed in relation to histological subtype and grade, surgicopathological staging parameters, MRI-measured tumor volume, and tumor apparent diffusion coefficient (ADC) value and clinical outcome. Results Tumor tissue had significantly higher ratios for tCho/Creatine, tCho/Water, and tCho/Noise than normal myometrial tissue ( P < 0.001 for all). High tumor tCho/Water ratio was significantly associated with high tumor grade in endometrioid tumors ( P = 0.02). Tumor tCho/Creatine ratio was positively correlated to MRI-measured tumor volume (rs = 0.25; P = 0.03). Conclusion High choline levels in tumor are associated with high-risk features. In vivo MRS may potentially aid in the preoperative risk stratification in endometrial cancer.

Entities:  

Keywords:  Endometrial neoplasms; choline; magnetic resonance imaging (MRI); magnetic resonance spectroscopy; risk assessment

Mesh:

Year:  2017        PMID: 28927296     DOI: 10.1177/0284185117733297

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  3 in total

1.  Magnetic resonance spectroscopy associations with clinicopathologic features of estrogen-dependent endometrial cancer.

Authors:  Jie Zhang; Qingwei Liu; Jie Li; Zhiling Liu; Ximing Wang; Na Li; Zhaoqin Huang; Han Xu
Journal:  BMC Med Imaging       Date:  2022-07-18       Impact factor: 2.795

2.  Metabolomic biomarkers in cervicovaginal fluid for detecting endometrial cancer through nuclear magnetic resonance spectroscopy.

Authors:  Shih-Chun Cheng; Kueian Chen; Chih-Yung Chiu; Kuan-Ying Lu; Hsin-Ying Lu; Meng-Han Chiang; Cheng-Kun Tsai; Chi-Jen Lo; Mei-Ling Cheng; Ting-Chang Chang; Gigin Lin
Journal:  Metabolomics       Date:  2019-10-29       Impact factor: 4.290

3.  Grading of endometrial cancer using 1H HR-MAS NMR-based metabolomics.

Authors:  Agnieszka Skorupa; Michał Poński; Mateusz Ciszek; Bartosz Cichoń; Mateusz Klimek; Andrzej Witek; Sławomir Pakuło; Łukasz Boguszewicz; Maria Sokół
Journal:  Sci Rep       Date:  2021-09-13       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.